Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
Lichen Jing, Xia Wu, Maxwell P. Krist, Tien-Ying Hsiang, Victoria L. Campbell, Christopher L. McClurkan, Sydney M. Favors, Lawrence A. Hemingway, Charmie Godornes, Denise Q. Tong, Stacy Selke, Angela C. LeClair, Chu-Woo Pyo, Daniel E. Geraghty, Kerry J. Laing, Anna Wald, Michael Gale Jr., David M. Koelle
Lichen Jing, Xia Wu, Maxwell P. Krist, Tien-Ying Hsiang, Victoria L. Campbell, Christopher L. McClurkan, Sydney M. Favors, Lawrence A. Hemingway, Charmie Godornes, Denise Q. Tong, Stacy Selke, Angela C. LeClair, Chu-Woo Pyo, Daniel E. Geraghty, Kerry J. Laing, Anna Wald, Michael Gale Jr., David M. Koelle
View: Text | PDF
Research Article Infectious disease

T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components

  • Text
  • PDF
Abstract

SARS-CoV-2 provokes a robust T cell response. Peptide-based studies exclude antigen processing and presentation biology, which may influence T cell detection studies. To focus on responses to whole virus and complex antigens, we used intact SARS-CoV-2 and full-length proteins with DCs to activate CD8 and CD4 T cells from convalescent people. T cell receptor (TCR) sequencing showed partial repertoire preservation after expansion. Resultant CD8 T cells recognize SARS-CoV-2–infected respiratory tract cells, and CD4 T cells detect inactivated whole viral antigen. Specificity scans with proteome-covering protein/peptide arrays show that CD8 T cells are oligospecific per subject and that CD4 T cell breadth is higher. Some CD4 T cell lines enriched using SARS-CoV-2 cross-recognize whole seasonal coronavirus (sCoV) antigens, with protein, peptide, and HLA restriction validation. Conversely, recognition of some epitopes is eliminated for SARS-CoV-2 variants, including spike (S) epitopes in the Alpha, Beta, Gamma, and Delta variant lineages.

Authors

Lichen Jing, Xia Wu, Maxwell P. Krist, Tien-Ying Hsiang, Victoria L. Campbell, Christopher L. McClurkan, Sydney M. Favors, Lawrence A. Hemingway, Charmie Godornes, Denise Q. Tong, Stacy Selke, Angela C. LeClair, Chu-Woo Pyo, Daniel E. Geraghty, Kerry J. Laing, Anna Wald, Michael Gale Jr., David M. Koelle

×

Figure 5

CD4 T cell coronavirus crossreactivity.

Options: View larger image (or click on image) Download as PowerPoint
CD4 T cell coronavirus crossreactivity.
(A) CD4 TCL from PBMC stimulated...
(A) CD4 TCL from PBMC stimulated with moDC and whole SARS-CoV-2 (subjects W001, W005, W012) or PBMC stimulated with whole SARS-CoV-2 (subject W003) recognize whole SARS-CoV-2, and sCoVOC43 or 229E antigens (V), but not mock (M) antigens. (B) CD4 TCL from subject W001 recognizes full-length S protein from OC43 but not empty vector control. (C) CD4 TCL recognize homologous S peptides from SARS-CoV-2 and OC43 in an HLA-DR–restricted fashion as indicated by inhibition with locus-specific mAb. An overlapping SARS-CoV-2 peptide shows DRB1*15:01 restriction at right. Conserved aa are underlined. Duplicate or triplicate raw data and mean bars are shown. Results are representative of 1–2 repeat experiments per panel.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts